# Prescribing characteristics and guideline concordance of antihypertensive western and Chinese patent medicine in Internet hospitals in China: a cross-sectional study

**Authors:** Tiantian Zhou, Xing Liao, Jiaxin Zuo, Fang Han, Ruogu Meng, Lin Zhuo, Guozhen Liu, Jing Hu

PMC · DOI: 10.3389/fphar.2025.1580787 · Frontiers in Pharmacology · 2025-04-28

## TL;DR

This study examines how antihypertensive medications are prescribed in China's Internet hospitals, finding that while Western medicine aligns with guidelines, Chinese patent medicine prescriptions often do not.

## Contribution

The study provides the first analysis of prescribing patterns and guideline adherence for antihypertensive Chinese patent medicine in Internet hospitals.

## Key findings

- Most antihypertensive prescriptions in Internet hospitals are for Western medicine, with calcium channel blockers being the most common.
- Only a small fraction of Chinese patent medicine prescriptions align with hypertension guidelines, and many lack traditional Chinese medicine syndrome diagnoses.
- Frequently prescribed Chinese patent medicine combinations are not recommended by guidelines, suggesting a need for improved management.

## Abstract

Internet hospitals have emerged as a vital approach for patients seeking treatment for hypertension, with a significant increase in antihypertensive medication prescriptions through these innovative models. However, prescribing characteristics and guideline concordance of these prescriptions remain unclear. This study aim to analyze the prescribing characteristics of Western medicine (WM) and Chinese patent medicine (CPM) for hypertension and assess their concordance with hypertension guidelines in Internet hospitals in China, providing insights for optimizing antihypertensive CPM management.

A cross-sectional analysis was conducted using data from the Yinchuan Internet Medical Regulatory Platform (YIMRP) covering 87 enterprise-led Internet hospitals in China from 1 January 2018, to 31 March 2021. Visits diagnosed with hypertension and prescribed at least one oral antihypertensive medication (either WM or CPM) were included. Guideline concordance was evaluated by comparing prescribed individual antihypertensive WM and CPM in Internet hospitals with international and Chinese hypertension guidelines recommendations. Statistical analyses included descriptive statistics, association rule analysis, and guideline concordance assessment.

Among the 787,209 visits, 93.75% were prescribed WM alone, 4.72% CPM alone, and 1.52% a combination of CPM and WM. Calcium channel blockers (CCBs) (38.50%) was the most prescribed WM class, with nifedipine (19.67%) being the most common individual medication. Most prescriptions of antihypertensive WM were guideline-concordant. Among CPM prescriptions, only 181 (0.37%) included traditional Chinese medicine (TCM) syndrome diagnoses. Of the 38 prescribed antihypertensive CPM, only 7 were guideline-recommended. The most frequently prescribed CPM were Jiuqiang Naoliqing (17.67%), and Zhenju Jiangya tablet (14.74%), neither of which was recommended by the guidelines. The combinations of two CPM were frequently prescribed, but none of these combinations were recommended by guidelines. The most common dual CPM combination was Jiuqiang Naoliqing + Qiangli Dingxuan tablet/capsule (support 8.65%, confidence 0.44%).

The prescribing characteristics of antihypertensive WM in Internet hospitals closely align with those in offline hospitals with relatively satisfactory guideline concordance. However, some issues persist in antihypertensive CPM prescriptions, including the lack of TCM syndrome differentiation, frequent prescription of non-recommended CPM, and duplicate therapies. Strengthening CPM management in Internet hospitals is essential for optimizing hypertension care.

## Full-text entities

- **Genes:** REN (renin) [NCBI Gene 5972] {aka ADTKD4, HNFJ2, RTD}
- **Diseases:** stroke (MESH:D020521), tachycardia (MESH:D013610), Coronary heart disease (MESH:D003327), Hypertension (MESH:D006973), target organ damage (MESH:D000092124), inflammatory (MESH:D007249), deaths (MESH:D003643), cardiac remodeling (MESH:D020257), myocardial infarction (MESH:D009203), XL (MESH:D000080345), migraine (MESH:D008881), angina (MESH:D000787), TCM syndrome (MESH:D013577), diabetes (MESH:D003920), ankle edema (MESH:D016512), retinopathy (MESH:D058437), CDSS (MESH:D020195), respiratory tract infection (MESH:D012141), hyperactivity (MESH:D006948), arrhythmia (MESH:D001145), atherosclerosis (MESH:D050197), gastrointestinal ulcer (MESH:D014456), headache (MESH:D006261), hypotension (MESH:D007022), hyperactivity of liver yang (MESH:D017093), CVD (MESH:D002318), urinary tract infection (MESH:D014552), hyperlipidemia (MESH:D006949), WM (MESH:D020241), TCM (MESH:C562377), cerebral infarctions (MESH:D002544), flushing (MESH:D005483), renal failure (MESH:D051437)
- **Chemicals:** amlodipine besilate (MESH:D017311), candesartan cilexetil (MESH:C077793), metoprolol tartrate (MESH:D008790), aldosterone (MESH:D000450), felodipine (MESH:D015736), nifedipine (MESH:D009543), Dingxuan (-), blood glucose (MESH:D001786)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12076013/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12076013/full.md

## References

63 references — full list in the complete paper: https://tomesphere.com/paper/PMC12076013/full.md

---
Source: https://tomesphere.com/paper/PMC12076013